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Abstract
Hepatocellular carcinoma (HCC) is a leading cause of 
cancer-related mortality worldwide, with the majority of 
cases associated with persistent infection from hepatitis 
B virus (HBV) or hepatitis C virus (HCV). Natural his-
tory studies have identified risk factors associated with 
HCC development among chronic HBV and HCV infec-
tion. High-risk infected individuals can now be identi-
fied by the usage of risk predictive scores. Vaccination 
plays a central role in the prevention of HBV-related 
HCC. Treatment of chronic HBV infection, especially by 
nucleoside analogue therapy, could also reduce the risk 
of HBV-related HCC. Concerning HCV infection, besides 
the advocation of universal precautions to reduce the 
rate of infection, pegylated interferon and ribavirin 
could also reduce the risk of HCV-related HCC among 
those achieving a sustained virologic response. Recently 
there has been mounting evidence on the role of che-
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HCC. The continued advances in the understanding of 
the molecular pathogenesis of HCC would hold promise 
in preventing this highly lethal cancer.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Hepatocellular carcinoma (HCC), with the ma-
jority of cases associated with infection from hepatitis 
B virus (HBV) or hepatitis C virus (HCV), is the most 
common primary liver tumor. We introduced risk factors 
and risk predictive scores associated with HCC develop-
ment among chronic HBV and HCV infection for its early 
diagnose and prevention. Vaccination plays a central 
role in the prevention of HBV-related HCC. Treatment of 
chronic HBV infection, especially by nucleoside analogue 
therapy, could reduce the risk of HBV-related HCC. Pe-
gylated interferon and ribavirin could reduce the risk of 
HCV-related HCC. Chemopreventive agents in reducing 
HBV- and HCV-related HCC were also discussed.
Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepa-
tocellular carcinoma in chronic viral hepatitis B and C infection. 




Hepatocellular carcinoma (HCC) is the most common 
primary liver tumor, and represents the third leading 
cause of  cancer death worldwide. It is the fifth most 
common cancer in men and seventh in women, ac-
counting for 7% of  all cancers[1]. Hepatocarcinogenesis 
is a multistep process mainly associated with persistent 
infection with hepatitis B virus (HBV) or hepatitis C 
virus (HCV)[2], which affects more than 350 and 170 mil-
lion individuals respectively worldwide. HCC is highly 
prevalent in regions endemic for chronic HBV and HCV 
infection[3].
The incidence of  HCC continues to increase world-
wide, with a unique geographic, age, and sex distribution. 
The most important risk factor associated with HCC is 
liver cirrhosis, which is again predominantly caused by 
chronic HBV or HCV infection. Primary prevention in 
the form of  HBV vaccination has led to a significant 
decrease in HBV-related HCC, and the antiviral therapy 
for chronic HBV and HCV infection also reduce the in-
cidence of  HBV- and HCV-related HCC[4].
China has one of  the highest carrier rates of  HBV in 
the world，reaching nearly 10% of  the general popula-
tion. The disease burden of  HBV infection and HCC is 
also believed to be among the world’s largest, and that of  
HCV infection is likely to be substantial as well[5].
RISK PREDICTION
An important component of  HCC prevention is the 
identification of  high-risk HBV- and HCV-infected indi-
viduals, who will benefit from various chemopreventive 
therapies discussed below. Several natural history studies 
have identified important risk factors for HCC among 
patients with chronic hepatitis B (CHB) and chronic hep-
atitis C (CHC), with risk predictive scores also designed 
for practical usage.
Risk factors and prediction scores: CHB
A study evaluating the relationship between serum HBV 
DNA level and risk of  HCC demonstrated that the in-
cidence of  HCC among CHB patients increased with 
serum HBV DNA level. Elevated serum HBV DNA 
level (≥ 2000 IU/mL) is a strong risk predictor of  HCC 
independent of  hepatitis B e antigen (HBeAg)-positivity, 
serum alanine aminotransferase levels, and liver cir-
rhosis[6]. Subsequent studies also showed patients with 
moderate levels of  serum HBV DNA (60-2000 IU/mL), 
when compared to individuals not infected with HBV, 
still had a substantial increased risk of  HCC and liver-
related death[7].
Besides serum HBV DNA levels, other host- and 
viral-related factors could also predispose to HCC. A 
meta-analysis found HBeAg-positive non-cirrhotic pa-
tients, when compared to HBeAg-positive cirrhotic pa-
tients, had a significantly reduced HCC risk after antiviral 
therapy[8]. HBV genotype also plays a role; HBV geno-
type C is closely associated with HCC especially in cir-
rhotic patients aged > 50 years[9]. An observation study in 
Hong Kong also found genotype C HBV infection to be 
an independent risk factor for HCC development when 
compared with genotype B[10].
Several clinical scoring systems have been developed 
for the prediction of  HCC in CHB, as depicted in Table 
1. These scoring systems are based on the longitudinal 
follow-up of  treatment-naïve CHB patients for 5 years or 
more. Two common parameters used are age and serum 
HBV DNA levels. Other parameters used include gender, 
serum alanine aminotransferase levels, serum albumin, 
HBeAg status, presence of  cirrhosis and presence of  
core promoter mutations[11-15]. Risk prediction is now 
also possible for CHB patients undergoing nucleoside 
analogue (NA) therapy. A recent study investigated the 
risk of  HCC among a large population of  CHB patients 
treated with entecavir. Older age and presence of  cir-
rhosis were independently associated with HCC in the 
entire cohort; advanced age and hypoalbuminemia were 
associated with HCC in patients without cirrhosis. The 
risk scores accurately predict which patients with CHB 
treated with entecavir would have a higher chance of  de-
veloping HCC[13]. 
Risk factors: CHC
When compared to CHB, fewer clinical scoring systems 
have been developed for the prediction of  HCV-related 
HCC. These are as depicted in Table 1. The majority of  
HCV-related HCC develop in patients with established 
cirrhosis. In a study investigating prognostic risk factors 
for HCV-related HCC, among 913 patients followed up 
for at least 3 years, age, male sex, portal hypertension, 
hepatic inflammation, and iron storage were significant 
risk factors for HCV-related HCC[16]. In a meta-analysis 
involving HCV-infected persons, sustained virologic 
response (SVR) was associated with reduced risk for 
HCC[17]. Even transient virologic control among patients 
with subsequent relapse after treatment, was associated 
with a lower risk of  the development of  HCC[18].
Prediction of  HCV-related HCC may be enhanced 
by the development of  related markers. Signal transducer 
and activator of  transcription 1 and phosphatase and ten-
sin homolog are associated with early growth response 
protein 1 signaling, which potentially promotes angio-
genesis, fibrogenesis, and tumorigenesis in HCV-related 
HCC. This approach has potential for the early diagnosis 
and possible prevention of  HCC. The corresponding se-
rum markers found can help to predict high-risk groups 
for HCC[19].
Host factors
HCC is more common in HBV carriers with a family his-
tory of  HCC. In a study of  5238 HBV carriers (553 with 
HCC and 4685 without HCC), the risk of  HCC was sig-
nificantly higher in those with a family history of  HCC, 
with a multivariate-adjusted rate ratio for HCC of  2.41 
compared with HBV carriers without a family history[20]. 
If  the carriers had two or more affected family members, 
the risk was even higher with the ratio increased to 5.55. 
It is therefore recommended to begin surveillance in 
adults once a family history of  HCC has been identified. 
A recently published study also included the presence of  
family history, besides traditional viral-related parameters 
as a component for risk prediction[15].
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PREVENTION OF HBV-RELATED HCC
HBV infection is the major cause of  HCC. Vaccination 
against HBV is instrumental in the prevention of  HCC, 
and is recommended for all newborns and individuals 
who are at increased risk for infection. Studies in Taiwan, 
where universal HBV vaccination was introduced in 
1984, have documented a significant decrease in the inci-
dence of  HCC in both children and adolescents after the 
introduction of  HBV vaccination as discussed below[21,22]. 
In patients already chronically infected with HBV, 
antiviral treatment could prevent disease progression to 
cirrhosis or HCC. Additionally, periodic surveillance us-
ing ultrasonography and serum α-fetoprotein every 3-6 
mo for earlier detection of  HCC is also important so 
that curative treatments (e.g., hepatic resection) can be 
offered[23].
The antiviral interventions and chemopreventive 
methods to prevent HBV-related HCC are summarized 
in Tables 2 and 3 respectively.
Vaccination
Vaccination plays a central role in HBV prevention strate-
gies worldwide, and a decline in the incidence and preva-
lence of  HBV infection following the introduction of  
universal HBV vaccination programs has been observed 
in many countries[24]. Control and significant reduction in 
incidence of  new HBV infections as well as HCC have 
been repeatedly reported in countries in East Asia and 
Africa[25]. 
A study of  the incidence of  HCC in children in 
Taiwan from 1981 to 1994 showed that the average an-
nual incidence of  HCC in children 6-14 years of  age 
declined from 0.70 per 100000 children (between 1981 
and 1986), to 0.57 per 100000 (between 1986 and 1990), 
and to 0.36 per 100000 (between 1990 and 1994). The 
corresponding rates of  mortality from HCC had also 
decreased. The incidence of  HCC in children 6-9 years 
of  age declined from 0.52 per 100000 (for those born 
between 1974 and 1984) to 0.13 per 100000 (for those 
born between 1984 and 1986). Since the institution of  
Taiwan’s program of  universal HBV vaccination from 
1984, the incidence of  HCC in children has declined 
dramatically[22]. The risk of  developing HCC for vac-
cinated cohorts was statistically significantly associated 
with incomplete HBV vaccination. The prevention of  
HCC by HBV vaccination extends from childhood to 
early adulthood. Failure to prevent HCC results mostly 
from unsuccessful control of  HBV infection by highly 
infectious mothers[21]. 
Antiviral therapy: Interferon and NAs
DNA integration of  hepatitis viruses alters the function 
of  critical genes, promoting malignant transformation 
of  virus-infected liver cells[26]. Treatment of  CHB infec-
tion aims to control viral replication and prevent the de-
velopment of  complications. There are currently seven 
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Table 1  Risk factors and prediction scores for hepatitis B 
virus- and hepatitis C virus-related hepatocellular carcinoma




Increased age √[11-15] √[16]
Male gender √[11,12,15] √[16]
Increased serum HBV DNA levels √[11,12,14,15]
Presence of cirrhosis √[12-14]
Increased serum ALT concentration √[11,15]
HBeAg positivity √[11,15]
Presence of core promoter mutations √[12]
Presence of virological remission 
after 24 mo
√[13]
Presence of hypoalbuminemia √[13]
Decreased serum albumin √[14]
Increased serum bilirubin √[14]
HBV genotype C √[15]
Presence of HBsAg √[15]
Family history of HCC √[15]
Presence of portal hypertension √[16]
Presence of hepatic inflammation √[16]
Increased iron storage levels √[16]
Presence of sustained virological 
response
√[17]
Presence of complete viral 
suppression
√[17]
HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular 
carcinoma; HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotrans-
ferase.
Table 2  Antiviral interventions for prevention of hepatitis B 
virus- and hepatitis C virus-related hepatocellular carcinoma
Antiviral interventions HBV-related HCC HCV-related HCC
IFN: IFN-α +/-[28,29] √[46]
   Pegylated IFN √[47]
NAs: Lamivudine √[36]
   Entecavir √[37,38]
Ribavirin √[47]
Vaccination √[21,22]
Screening of blood product √[27] √[27]
HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular car-
cinoma; IFN: Interferon; NA: Nucleotide analogs.
Table 3  Chemopreventive agents for hepatitis B virus- and 
hepatitis C virus-related hepatocellular carcinoma
Chemopreventive agents HBV-related HCC HCV-related HCC
Statins √[42]




Dietory agents: Coffee √[54] √[54]
Vitamin E √[54] √[54]
Vitamin D √[50]
Fish oil (n-3 PUFA) √[55-57] √[55-57]
Phytochemicals: Resveratrol √[43]
EGb √[44]
HBV: Hepatitis B virus; HCV: Hepatitis C virus; HCC: Hepatocellular 
carcinoma; PUFA: Polyunsaturated fatty acid; FASN: Fatty acid synthase; 
EGb: Extract of ginkgo biloba leaf.
Lu T et al . Prevention of HCC in CHB and CHC infection
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Patients without cirrhosis benefit more from NA than 
those with cirrhosis, although resistance to NA blunts the 
benefit of  treatment[8]. 
In summary, while the evidence of  the efficacy of  
IFN in preventing HBV-related HCC remains conflicting, 
there is a gradual accumulation of  evidence supporting 
the positive effect of  NA on reducing HBV-related HCC.
Chemoprevention
The observation that anti-platelet therapy inhibits or 
delays immune-mediated hepatocarcinogenesis suggests 
that platelets may be one of  the key players in the patho-
genesis of  HBV-associated liver cancer and that immune-
mediated necroinflammatory reactions may be an impor-
tant cause of  malignant transformation during chronic 
hepatitis[38]. A prospective study on 300504 patients with 
chronic liver disease showed that aspirin users had statis-
tically significant reduced risks of  incidence of HCC and 
mortality due to chronic liver disease compared to those 
who did not use aspirin[39]. Further studies are needed to 
confirm this finding and clarify its underlying mechanism. 
A study concerning the association between the use 
of  statins in HBV-infected patients and the risk of  HCC 
shows that statin use may reduce the risk for HCC in 
HBV-infected patients in a dose-dependent manner[40]. 
This may be related to the effect of  statins in reducing 
fatty change in the liver, and requires future validation 
studies to confirm the findings.
There are also several investigational drugs which 
could have potential for chemoprevention against HBV-
related HCC. Resveratrol is a natural polyphenol that has 
beneficial effects across various disease models. In an ani-
mal study investigating the efficacy of  resveratrol against 
HBV-related HCC in HBV X protein (HBx) transgenic 
mice, resveratrol had a pleiotropic effect on HBx trans-
genic mice in terms of  the down-regulation of  lipogene-
sis, the promotion of  transient liver regeneration, and the 
stimulation of  antioxidant activity. Furthermore, at later 
precancerous stages, resveratrol delayed HBx-mediated 
hepatocarcinogenesis and reduced HCC incidence from 
80% to 15%. The potential mechanisms for resveratrol 
on HCC prevention might be associated with its ef-
fects of  stimulating the activity of  Ampk and SirT1, and 
downregulating the expression of  the lipogenic genes, 
Srebp1-c and peroxisome proliferator-activated receptor 
gamma. The decrease in Srebp1-c further downregulates 
the expression of  its target genes, Acc and Fas[41]. Several 
other studies demonstrated resveratrol downregulates 
cyclin D1 as well as p38 MAP kinase, suppresses Akt and 
Pak1 expression and activity, and increases ERK activity, 
suggesting that growth inhibitory activity of  resveratrol is 
associated with the downregulation of  cell proliferation 
and survival pathways, and sensitization to apoptosis[42]. 
Resveratrol also acts as an inhibitor for sirtuins. Over-
expression of  SIRT1 in cancer tissue has been demon-
strated to promote mitotic entry of  liver cells, cell growth 
and proliferation, and inhibit apoptosis related to the 
PTEN/PI3K/AKT signaling pathway[43,44].
drugs available for the treatment of  CHB, five NAs and 
two interferon (IFN)-based therapies. Long-term treat-
ment with NA is often required, and the decision to treat 
is based on the clinical assessment including the phase 
of  CHB infection and the presence and extent of  liver 
damage[24].
Concerning IFN therapy, a study involving 641 biop-
sy-proven CHB patients treated with IFN-α2b were fol-
lowed up for a median period of  113 months. Although 
HCC occurred less frequently in biochemical responders 
than in non-responders, virologic response is not associ-
ated with decrease in HCC development. Poor biochemi-
cal response, as well as older age and a higher serum AFP 
level remain independent predisposing factors of  HCC 
development in CHB patients treated with IFN-α[27]. In 
addition, a study about the long-term effects of  IFN-α 
in Chinese patients showed that IFN-α was of  no long-
term benefit in inducing HBeAg seroconversion or in 
the prevention of  HCC and other cirrhosis-related com-
plications[28].
On the contrary, nearly all the studies showed that 
NA is able to reduce HCC[29]. Many randomized con-
trolled trials showed that lamivudine, one of  the earliest 
oral NAs for antiviral therapy in HBV infection, can 
reduce disease progression in HBV-related cirrhosis and 
HCC[29-34]. A recent study followed up 293 CHB patients 
without HCC who were treated with lamivudine for a 
mean duration of  67.6 mo. In cirrhotic patients, the at-
tainment of  maintained viral response (defined as HBV-
DNA levels of  < 4.0 log copies/mL) during lamivudine 
treatment was revealed to reduce the risk of  HCC devel-
opment. No significant reduction was observed in the 
non-cirrhotic group[35]. 
Entecavir is a potent NA with high genetic barrier to 
resistance, and prolonged treatment results in regression 
of  fibrosis, hence is currently recommended as first-line 
antiviral therapy for CHB. In a study of  CHB patients 
with liver cirrhosis, entecavir therapy reduces the risks of  
hepatic complications, HCC, liver-related and all-cause 
mortality of  CHB patients with liver cirrhosis in 5 years, 
particularly among those who had sustained viral sup-
pression[36]. In another multicentre cohort study, 372 en-
tecavir-treated patients followed up for a mean duration 
of  114 mo were investigated. Clinical events were defined 
as development of  HCC, hepatic decompensation or 
death. Virological response to entecavir (HBV DNA < 
80 IU/mL) was associated with a lower probability of  
disease progression in patients with cirrhosis, suggesting 
that complete viral suppression is essential for NA treat-
ment, especially in patients with cirrhosis[37]. 
A meta-analysis investigating the effects of  IFN or 
NA on the risk of  developing HCC in CHB patients 
shows that, the reduction in HCC is more significant 
among patients with early cirrhosis than among non-cir-
rhotic patients. Five studies (n = 2289) compared patients 
treated by NA with control. The risk of  HCC after treat-
ment is reduced by 78%. HBeAg-positive patients have 
a more significant reduction in HCC risk with treatment. 
Lu T et al . Prevention of HCC in CHB and CHC infection
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A study in China suggested that extract of  Ginkgo Bi-
loba leaf  (EGb) could reduce the incidence of  the HCC 
with HBV transgenic mice. The reason may be that EGb 
could reduce liver HBx, p53, Bcl-2 protein expression in 
HBV transgenic mice[45]. These investigational products 
would need confirmation in human clinical trials in the 
future. 
PREVENTION OF HCC RELATED TO HCV
With the commencement of  successful vaccination 
programs against HBV, CHC is now emerging as an 
important cause of  chronic liver diseases. The drive of  
carcinogenesis during HCV infection is thought to result 
from the interactions of  viral proteins with host cell pro-
teins. Thus, the induction of  liver mutation phenotypes 
through the expression of  HCV proteins provides a key 
mechanism for the development of  HCV-associated 
HCC. With the emerging importance of  CHC, mecha-
nisms of  HCV-associated hepatocellular carcinogenesis 
should be clarified to provide insight into advanced 
therapeutic and preventive approaches to decrease the 
incidence and mortality of  HCC[46].
Strategies aimed at eliminating the virus may provide 
opportunities for effective prevention of  the develop-
ment of  HCC. The first step is to encourage universal 
precautions to reduce infections transmitted via different 
modalities e.g., iatrogenic routes, sharing of  intravenous 
needles etc and further implementation of  universal 
screening of  donated blood products. Concerning ther-
apy for HCV, pegylated IFN plus ribavirin therapy is ef-
fective at reducing the risk of  HCC in patients with CHC 
who achieve SVR. 
The effects of  antiviral therapy and chemopreventive 
measures in preventing HCC are mentioned in Tables 2 
and 3 respectively.
Antiviral therapy: IFN and ribavirin
Current strategies to reduce HCC incidence in CHC 
patients include prevention of  cirrhosis development by 
avoiding metabolic, pharmacological, or social factors 
associated with accelerated progression of  liver disease, 
or through virus eradication by IFN-based treatments. 
Moreover, a successful antiviral treatment has positive 
impact on the rate of  HCC development in patients who 
are already cirrhotic[1].
Combination of  pegylated IFN and ribavirin therapy 
is recommended for antiviral therapy worldwide, and 
is effective in reducing the rate of  recurrence of  HCV-
associated HCC after curative resection or transplanta-
tion[47]. The pooling of  data from the literature suggests 
a preventive effect of  antiviral therapy on HCC devel-
opment in patients with HCV-related cirrhosis, but the 
preventive effect is limited to those achieving SVR[48]. 
However, some HCV mutations, such as the amino acid 
substitution M91L, are associated with treatment failure 
and a poor prognosis[47].
There is a recent study of  the effect of  pegylated 
IFN and ribavirin treatment of  CHC on the incidence 
of  HCC. After a median observation period of  3.6 
years, a significantly lower rate of  HCC incidence was 
noted in patients achieving SVR when compared to non-
virological responders. A similarly lower rate of  HCC 
incidence was noted among cirrhotic patients achieving 
SVR (18.9%) when compared to cirrhotic non-virological 
responders (39.4%)[18]. 
A meta-analysis study has been performed recently 
with the data sources from MEDLINE, EMBASE, CI-
NAHL, the Cochrane Library, Web of  Science, and the 
Database of  Abstracts of  Reviews and Effectiveness 
from inception through 2012, to systematically review 
observational studies to determine the association be-
tween response to HCV therapy and development of  
HCC among persons at any stage of  fibrosis and those 
with advanced liver disease. Among HCV-infected per-
sons, there is moderate-quality evidence demonstrating 
SVR to be associated with reduced risk for HCC; SVR 
after treatment among HCV-infected persons at any stage 
of  fibrosis is associated with reduced HCC[17]. 
Chemoprevention
Vitamin D insufficiency has been associated with the 
occurrence of  various types of  cancer. A recent study 
aimed to determine the relationship between genetic de-
terminants of  vitamin D serum levels and the risk of  de-
veloping HCV-related HCC. The data suggest a relatively 
weak but functionally relevant role for vitamin D in the 
prevention of  HCV-related hepatocarcinogenesis[49].
Propranolol has antioxidant, anti-inflammatory, anti-
angiogenic properties and antitumoral effects and there-
fore is potentially active in the prevention of  HCC. A 
retrospective long-term observational study suggests that 
propranolol treatment might decrease HCC occurrence 
in patients with HCV cirrhosis[50]. These findings also 
need to be verified by prospective clinical trials. 
Understanding the interplay between the viral and cel-
lular components of  the HCV replication complex could 
provide new insight for prevention of  the progression 
of  HCV-associated HCC. Fatty acid synthase (FASN) is 
found to interact with NS5B. FASN may thereby serve as 
a target for the treatment of  HCV infection and the pre-
vention of  HCV-associated HCC progression[51]. Thus, 
understanding the molecular mechanisms, which are im-
plicated in the development of  HCC during the course 
of  HCV infection, may help to design a general therapeu-
tic protocol for the treatment and for its prevention.
PREVENTION OF HCC RELATED TO HBV 
AND HCV COINFECTION
HBV and HCV coinfection is not uncommon with an 
estimated 7-20 million infected individuals worldwide[52]. 
A community-based prospective cohort study evaluating 
HCC development in HBV and HCV co-infected sub-
jects found the hazard ratios (HRs) of  HBV monoinfec-
tion, HCV monoinfection, and HBV/HCV coinfection 
were 17.1, 10.4 and 115.0, respectively. Different geno-
Lu T et al . Prevention of HCC in CHB and CHC infection
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types and multiplicative synergistic effect of  HBV and 
HCV coinfection on HCC risk was observed. Infection 
with HCV genotype 1 (HR = 29.7) and mixed infection 
with genotype 1 and 2 (HR = 68.7) significantly elevated 
HCC risk, much higher than HBV infection. The effect 
of  different HCV genotypes and the multiplicative syn-
ergistic effect of  HBV/HCV coinfection on HCC risk 
underline the need for comprehensive identification of  
hepatitis infection status in order to prevent and control 
HCC[53]. 
Pegylated interferon-alpha plus ribavirin should be 
recommended in patients with dominant HCV replica-
tion. However, HBV rebound may occur after elimina-
tion of  HCV with anti-HBV treatment required. These 
therapeutic measures may contribute to the prevention 
of  HCC this special group of  patients[52].
OTHER POTENTIAL CHEMOPREVENTIVE 
METHODS
The use of  aspirin, but not nonsteroidal anti-inflammato-
ry drugs, is associated with a decreased risk of  HCC and 
death from chronic liver disease in the National Institutes 
of  Health-AARP Diet and Health Study of  patients be-
tween the ages of  50 and 71 years[39]. However this study 
does not provide information on the HBV and HCV 
status of  its participants, and would need confirmation 
by future studies specifically for the HBV- and HCV-
infected population.
More recent data have suggested dietary factors, in-
cluding increased intake of  coffee[54], unsaturated fatty ac-
ids and fish to be protective against HCC. Subjects with 
known HBV or HCV status, and subjects who were anti-
HCV and/or hepatitis B surface antigen positive were 
analysed. Consumption of  n-3 polyunsaturated fatty acid 
(PUFA)-rich fish or n-3 PUFAs, particularly eicosapen-
taenoic acid, docosapentaenoic acid, and docosahexae-
noic acid, appears to protect against the development of  
HCC, even among subjects with HBV and/or HCV in-
fection[55], probably through dampening the inflammation 
in the liver and decreasing formation of  tumor necrosis 
factor (TNF)-α, and through simultaneously inhibition 
of  COX-2 and beta-catenin[56,57]. The findings also point 
to a potential anticancer role for the n-3 PUFA-derived 
lipid mediators 18-HEPE and 17-HDHA, which can 
down-regulate the important proinflammatory and pro-
liferative factor TNF-α.
CONCLUSION
Clinical experts evaluated ten previously identified dimen-
sions of  HCC control: clinical education; risk assessment; 
HBV strategy; HCV strategy; life-style risk factors; na-
tional statistics; funding for screening; funding for treat-
ment; political awareness; and public awareness. Of  these 
strategies, the most significant needs in regional efforts 
to control HCC are political awareness, public awareness, 
and life-style risk factors[58].
HCC is a challenging malignancy of  global impor-
tance. As HCC is strongly associated with chronic viral 
hepatitis, prevention against the infection is crucial for 
prevention against HCC. Vaccination against HBV in the 
newborns and early childhood is highly effective to lower 
infection rates substantially. For HCV, universal precau-
tions when dealing with human blood, education on 
high-risk behaviours and screening programs for blood 
donors can reduce infection rates. Although prevention 
and treatment of  CHB and CHC have been improved 
within the last decades even in high-risk countries, further 
effective and sustainable reduction of  these infections is 
still needed[26]. 
Antiviral therapies for CHB and CHC, while impor-
tant, can only reduce but not completely eliminate HCC. 
Improvement in identification of  infected persons, acces-
sibility of  care and affordability of  treatment are needed 
for antiviral therapy to have a major impact on the global 
incidence of  HCC[59]. Further advances in our under-
standing of  the molecular pathogenesis of  HCC hold 
promise in improving the diagnosis and treatment of  this 
highly lethal cancer[4].
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